Table 1.
Patient characteristics
| Sirolimus (N=61) | CNI (N=85) | P | |
|---|---|---|---|
| Recipient age, yrs | 56±11 | 53±14 | 0.16 |
| Male sex, n (%) | 43 (70) | 65 (76) | 0.42 |
| Time since heart transplant, yrs | 2.5 (1.2, 7.0) | 2.9 (0.2, 8.5) | 0.38 |
| Donor age, yrs | 29±13 | 30±13 | 0.82 |
| Previous CMV infection, n (%) | 17 (28) | 22 (26) | 0.79 |
| Treatment episodes of rejection, n (%) | |||
| Baseline | 10 (16) | 13 (15) | 0.86 |
| During follow-up period | 2 (3) | 7 (8) | 0.22 |
| Comorbidities | |||
| BMI, kg/m2 | |||
| Baseline | 27.5±5.1 | 26.9±5.5 | 0.52 |
| Follow-up | 28.3±5.8* | 27.6±5.3* | 0.45 |
| Diabetes, n (%) | |||
| Baseline | 14 (23) | 19 (22) | 0.93 |
| Follow-up | 14 (23) | 19 (22) | 0.93 |
| Hypertension, n (%) | |||
| Baseline | 48 (79) | 58 (68) | 0.16 |
| Follow-up | 47 (77) | 57 (67) | 0.19 |
| Total cholesterol, mg/dl | |||
| Baseline | 198±46 | 184±47 | 0.07 |
| Follow-up | 194±57 | 177±48 | 0.06 |
| Triglyceride, mg/dl | |||
| Baseline | 148 (114, 222) | 128 (87, 193) | 0.06 |
| Follow-up | 168 (120, 226) | 135 (86, 191) | 0.01 |
| HDL cholesterol. mg/dl | |||
| Baseline | 55±17 | 54±18 | 0.59 |
| Follow-up | 50±16‡ | 52±14 | 0.36 |
| LDL cholesterol, mg/dl | |||
| Baseline | 109±34 | 100±35 | 0.12 |
| Follow-up | 100±30 | 93±37 | 0.26 |
| Serum creatinine, mg/dl | |||
| Baseline | 1.4±0.6 | 1.4±0.3 | 0.94 |
| Follow-up | 1.2±0.4* | 1.4±0.6 | 0.04 |
| Medication | |||
| Aspirin, n (%) | |||
| Baseline | 17 (28) | 23 (27) | 0.91 |
| Follow-up | 19 (31) | 25 (29) | 0.82 |
| ACE inhibitor, n (%) | |||
| Baseline | 25 (41) | 29 (34) | 0.40 |
| Follow-up | 24 (39) | 30 (35) | 0.61 |
| CCB, n (%) | |||
| Baseline | 13 (21) | 26 (31) | 0.21 |
| Follow-up | 14 (23) | 28 (33) | 0.19 |
| Statin, n (%) | |||
| Baseline | 56 (92) | 72 (85) | 0.19 |
| Follow-up | 57 (93) | 75 (88) | 0.29 |
| Immunosuppressants | |||
| Sirolimus, n (%) | 61 (100) | - | |
| Cyclosporin, n (%) | - | 61 (72) | |
| Tacrolimus, n (%) | - | 24 (28) | |
| Azathioprine, n (%) | 25 (41) | 25 (29) | 0.15 |
| MMF, n (%) | 35 (57) | 57 (67) | 0.23 |
Data are expressed as mean±SD, median (interquartile range) or n (%).
*
P<0.05
†P<0.01
‡
P<0.001 vs. baseline.
ACE indicates angiotensin-converting enzyme; BMI, Body mass index; CCB, calcium channel blocker; CMV, cytomegalovirus; CNI, calcineurin inhibitors; HDL, high-density lipoprotein; IVUS, intravascular ultrasound; LDL, low-density lipoprotein; and MMF, mycophenolate mofetil.